CRVS — Corvus Pharmaceuticals, Inc. stock price, charts and financials
QT83Corvus Pharmaceuticals, Inc.Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | - | Insider Own | 37.56% | Shs Outstand | 84.09M | Perf Week | -2.71% |
| Market Cap | 1.06B | Forward P/E | - | EPS next Y | -0.93 | Insider Trans | 0.09% | Shs Float | 72.76M | Perf Month | -18.44% |
| Enterprise Value | 1.04B | PEG | 0.09 | EPS next Q | -0.21 | Inst Own | - | Short Float | 26.14% | Perf Quarter | 5.46% |
| Income | -49.32M | P/S | 0.00 | EPS this Y | - | Inst Trans | - | Short Ratio | 17.61 | Perf Half Y | -10.86% |
| Sales | 0.00 | P/B | 5.15 | EPS next Y | -24.31% | ROA | -22.62% | Short Interest | 19.02M | Perf YTD | 63.12% |
| Book/sh | - | P/C | - | EPS next 5Y | - | ROE | -36.15% | 52W High | 26.95 -53.40% | Perf Year | 116.93% |
| Cash/sh | - | P/FCF | - | EPS past 3/5Y | - | ROIC | -25.20% | 52W Low | 5.74 118.82% | Perf 3Y | 670.55% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | - | Gross Margin | 0.00% | Volatility | 4.43% 4.38% | Perf 5Y | 406.45% |
| Dividend TTM | - | EV/Sales | 0.00 | EPS Y/Y TTM | 40.20% | Oper. Margin | 0.00% | ATR (14) | 0.66 | Perf 10Y | -15.93% |
| Dividend Ex-Date | - | Quick Ratio | 16.16 | Sales Y/Y TTM | - | Profit Margin | 0.00% | RSI (14) | 36.47 | Recom | 2.08 |
| Dividend Gr. 3/5Y | - | Current Ratio | 16.16 | EPS Q/Q | -90.00% | SMA20 | -8.58% | Beta | 1.49 | Target Price | 40.00 |
| Payout | 0.00% | Debt/Eq | 0.00 | Sales Q/Q | - | SMA50 | -10.45% | Rel Volume | 4.14 | Prev Close | 12.55 |
| Employees | 37 | LT Debt/Eq | 0.02 | Earnings | Nov 03 | SMA200 | -10.19% | Avg Volume | 1.08M | Price | 12.56 |
| IPO Date | Mar 23, 2016 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -19.41% - | Net Debt/EBITDA | 0.35 | Volume | 4,460,289 | Change | 0.08% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Apr-17-26 | Initiated | Goldman Sachs | Buy | $40 |
| Jan-29-26 | Reiterated | Mizuho Securities | Outperform | $20 → $30 |
| Jan-22-26 | Reiterated | Jefferies | Buy | $13 → $42 |
| Jan-21-26 | Reiterated | Oppenheimer | Outperform | $7.00 → $32 |
| Jan-20-26 | Reiterated | Mizuho Securities | Outperform | $13 → $20 |
| Jan-20-26 | Reiterated | HC Wainwright & Co. | Buy | $27 |
| Oct-29-25 | Reiterated | Mizuho Securities | Outperform | $11 → $13 |
| Oct-13-25 | Initiated | Barclays | Overweight | $16 |
| May-20-25 | Reiterated | Mizuho | Outperform | $12 → $11 |
| Nov-13-24 | Reiterated | Jefferies | Buy | $13 |
Corvus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm specializing in the development and commercialization of immuno-oncology therapies. Their leading investigational compound, Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody, is currently progressing through Phase Ib/II clinical trials for the treatment of non-small cell lung cancer and head and neck cancers. Another promising candidate, CPI-818, functions as a covalent ITK inhibitor. This therapy is undergoing Phase I/Ib clinical evaluation for patients battling various malignant T-cell lymphomas, aiming to impede the proliferation of specific malignant T-cells. Additionally, Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, is in Phase II clinical trials for individuals diagnosed with either advanced or refractory renal cell carcinoma. Beyond these clinical-stage assets, Corvus maintains a preclinical portfolio including CPI-182, an antibody designed to block inflammation and myeloid suppression, and CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. The company also benefits from a strategic collaboration with Angel Pharmaceuticals, which aids in advancing its diverse pipeline of targeted experimental drugs. Founded in 2014, Corvus Pharmaceuticals is headquartered in Burlingame, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | FY 2018 12/31/2018 | FY 2017 12/31/2017 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 0 | 0 | 0 | — | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 0 | 0 | 0 | — | — | — | — | — | — | |
| Gross Profit | 0 | 0 | 0 | — | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 9 | 8 | 7 | — | — | — | — | — | — | |
| Research and Development | 34 | 19 | 17 | — | — | — | — | — | — | |
| Other Operating Expense | 0 | 1 | -1 | — | — | — | — | — | — | |
| Operating Income | -43 | -28 | -23 | — | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 28 | -35 | -4 | — | — | — | — | — | — | |
| Net Income Before Taxes | -15 | -62 | -27 | — | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | — | |
| Consolidated Net Income | -15 | -62 | -27 | — | — | — | — | — | — | |
| Net Income From Continuing Operations | -15 | -62 | -27 | — | — | — | — | — | — | |
| Net Income | -15 | -62 | -27 | — | — | — | — | — | — | |
| EPS (Recurring) | -0.19 | -1.02 | -0.56 | — | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -0.19 | -1.02 | -0.56 | — | — | — | — | — | — | |
| EPS (Diluted) | -0.53 | -1.02 | -0.56 | — | — | — | — | — | — | |
| EBITDA | -15 | -62 | -27 | — | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | — | — | — | — | — | — | — | — | — | |
| Gross Margin | — | — | — | — | — | — | — | — | — | |
| Operating Margin | — | — | — | — | — | — | — | — | — | |
| Net Margin | — | — | — | — | — | — | — | — | — | |
| Shares Outstanding | 79 | 61 | 48 | — | — | — | — | — | — | |
| Market Capitalization | 608 | 326 | 84 | — | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Moore David Scott | Director | Jun 11 '26 | Buy | 11.53 | 21,700 | 250,236 | 21,700 | Jun 15 |
| MILLER RICHARD A MD | President and CEO | May 18 '26 | Buy | 12.04 | 6,932 | 83,453 | 1,195,035 | May 20 |
| Thompson Peter A. | director, 10 percent owner: | Jan 28 '26 | Option Exercise | 5.33 | 210,000 | 1,119,374 | 210,000 | Jan 30 |
| ORBIMED ADVISORS LLC | director, 10 percent owner: | Jun 27 '25 | Option Exercise | 3.50 | 1,397,684 | 4,891,894 | 8,341,338 | Jul 01 |
| ORBIMED ADVISORS LLC | director, 10 percent owner: | Jun 27 '25 | Sale | 4.16 | 1,176,332 | 4,891,894 | 7,165,006 | Jul 01 |
| Thompson Peter A. | director, 10 percent owner: | Jun 27 '25 | Option Exercise | 3.50 | 1,397,684 | 4,891,894 | 8,341,338 | Jul 01 |
| Thompson Peter A. | director, 10 percent owner: | Jun 27 '25 | Sale | 4.16 | 1,176,332 | 4,891,894 | 7,165,006 | Jul 01 |
| Jones William Benton | See Remarks | Jun 04 '25 | Option Exercise | 3.50 | 19,357 | 67,750 | 173,130 | Jun 06 |
| MILLER RICHARD A MD | President and CEO | May 07 '25 | Option Exercise | 3.50 | 559,073 | 1,956,756 | 1,136,707 | May 09 |
| Thompson Peter A. | director, 10 percent owner: | May 06 '24 | Buy | 1.72 | 2,841,769 | 4,892,038 | 1,444,085 | May 08 |
| ORBIMED ADVISORS LLC | director, 10 percent owner: | May 06 '24 | Buy | 1.72 | 2,841,769 | 4,892,038 | 1,444,085 | May 08 |
| Jones William Benton | See Remarks | May 06 '24 | Buy | 2.60 | 39,357 | 102,374 | 153,773 | May 07 |
| MILLER RICHARD A MD | President and CEO | May 06 '24 | Buy | 2.60 | 1,136,707 | 2,956,756 | 577,634 | May 07 |
| Grais Linda | Director | May 15 '23 | Buy | 2.45 | 10,000 | 24,500 | 10,000 | May 16 |
| Jones William Benton | See Remarks | Dec 20 '22 | Buy | 0.79 | 20,000 | 15,800 | 133,773 | Dec 20 |